GILUPI Nanomedizin

Karriere

Die 2006 gegründete GILUPI GmbH, mit Hauptsitz im Technologiepark Potsdam Golm, entwickelt einen bereits patentierten medizinischen Detektor. Dabei konzentriert sich die GILUPI GmbH auf die Isolierung seltener Zellen aus dem Blutkreislauf für den Pränatal- und Krebsdiagnostik-Markt.

Innovationen unternehmerisch denkender und handelnder Mitarbeiter charakterisieren den bisherigen Erfolg.

derzeit stehen keine freien Stellen zur Verfügung

Life Science News (bionity.com)

Q-Biologicals signs a service framework agreement with Bayer CropScience Q-Biologicals, a biotech company focused on providing services in the field of process development and manufacturing of recombinant proteins, viruses and live cells, announced that it has entered into a service framework agreement with Bayer CropScience to produce and purify recombinant proteins for...
VTT searches for novel biomarkers and targets for preventing or treating type 2 diabetes VTT is participating in two new European projects focusing on type 2 diabetes. The projects aim at identifying new therapeutic choices and strategies for preventing the disease. Focus is on obtaining information on cellular dysfunction in diabetes and the effects of changes in lifestyle. The goal i...
Abbott Receives Positive Opinion for HUMIRA in Ulcerative Colitis from EMA's CHMP Abbott announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HUMIRA® (adalimumab) in adults with moderate to severely active ulcerative colitis (UC) who have not responded to, cannot tolerate or have medical contraindications to conventio...